Author

Wenwei Lin

St. Jude Children's Research HospitalORCID 0000-0001-8754-6150Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Wenwei Lin2 papers · Fujian Agriculture and Forestry University

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:clustering· 1 Approach:deep learning· 1

Frequent Co-Authors

Taosheng CheniD· 2 shared A Wang· 1 shared Aaron B. TayloriD· 1 shared Adithi DandaiD· 1 shared Amar J. GajjariD· 1 shared Anang A. ShelatiD· 1 shared Aseem Z. AnsariiD· 1 shared Ashraf MohammediD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

Taosheng ChenORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cell BiologybioRxivPreprintApr 13, 2026

BRD4 recruitment desilences transcription without erasure or depletion of repressive chromatin

Christopher J. Brandon, Sarah Robinson-Thiewes, Mangesh H. Kaulage…·Aseem Z. Ansari

This study shows that BRD4 recruitment can desilence transcription within repressive chromatin without removing H3K9me3 or HP1, challenging conventional models of chromatin regulation.

DOI 10.64898/2026.04.10.717856

𝕏 PostBluesky

Cancer BiologybioRxivPreprintNov 20, 2025

Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastoma

Jingjing Liu, Yang Xu, Mingrui Zhu…·Jiyang Yu

The paper introduces SINBA, a computational framework that identifies synergistic, brain-penetrant drug combinations for high-risk medulloblastoma, validating several candidates in preclinical models.

DOI 10.1101/2025.11.20.689490

mousebulk RNA-seq

𝕏 PostBluesky